BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30467200)

  • 21. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
    Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
    Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
    Silverman LB; Supko JG; Stevenson KE; Woodward C; Vrooman LM; Neuberg DS; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Laverdière C; Michon B; Schorin M; Schwartz CL; O'Brien JE; Cohen HJ; Sallan SE
    Blood; 2010 Feb; 115(7):1351-3. PubMed ID: 20007809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review.
    Oparaji JA; Rose F; Okafor D; Howard A; Turner RL; Orabi AI; Byersdorfer C; Mi Q; Ritchey K; Lowe ME; Husain SZ
    J Clin Gastroenterol; 2017; 51(10):907-913. PubMed ID: 28375864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.
    Kutszegi N; Semsei ÁF; Gézsi A; Sági JC; Nagy V; Csordás K; Jakab Z; Lautner-Csorba O; Gábor KM; Kovács GT; Erdélyi DJ; Szalai C
    PLoS One; 2015; 10(10):e0140136. PubMed ID: 26457809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
    Malbora B; Avci Z; Ozbek N
    Drug Chem Toxicol; 2012 Oct; 35(4):463-6. PubMed ID: 22149271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
    J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
    Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
    Kearney SL; Dahlberg SE; Levy DE; Voss SD; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2009 Aug; 53(2):162-7. PubMed ID: 19405141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
    Aydin Köker S; Oymak Y; Demirağ B; Karapinar TH; Koker A; Genç S; Erdemir G; Vergin RC
    Clin Ther; 2020 Apr; 42(4):e82-e86. PubMed ID: 32184014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
    Hijiya N; van der Sluis IM
    Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia.
    Grimes AC; Chen Y; Bansal H; Aguilar C; Perez Prado L; Quezada G; Estrada J; Tomlinson GE
    Support Care Cancer; 2021 Feb; 29(2):725-731. PubMed ID: 32447501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
    Højfeldt SG; Wolthers BO; Tulstrup M; Abrahamsson J; Gupta R; Harila-Saari A; Heyman M; Henriksen LT; Jónsson ÒG; Lähteenmäki PM; Lund B; Pruunsild K; Vaitkeviciene G; Schmiegelow K; Albertsen BK;
    Br J Haematol; 2019 Feb; 184(3):405-417. PubMed ID: 30450575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
    Wu SF; Chen AC; Peng CT; Wu KH
    Pediatr Blood Cancer; 2008 Dec; 51(6):824-5. PubMed ID: 18726919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Mootoosamy C; Kondyli M; Serfaty SA; Tremblay DÉ; Gagné V; Ribère M; Laverdière C; Leclerc JM; Sinnett D; Tran TH; Krajinovic M
    Pharmacogenomics; 2023 Mar; 24(4):199-206. PubMed ID: 36946317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.